Callodine Capital Management LP Has $22.52 Million Stake in Sanofi $SNY

Key Points

• Callodine Capital Management LP increased its stake in Sanofi by 5.7% in Q1, holding 405,969 shares valued at approximately $22.5 million, making it the firm's 10th largest position.
• Sanofi's latest quarterly earnings showed a net margin of 21.47% with a revenue of $11.34 billion, however, it missed EPS estimates by $0.06.
• Analysts have a consensus rating of "Buy" on Sanofi with a target price of $62.00, reflecting optimism about the company's future performance.

Callodine Capital Management LP grew its holdings in Sanofi (NASDAQ:SNY - Free Report) by 5.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 405,969 shares of the company's stock after purchasing an additional 21,780 shares during the quarter. Sanofi comprises about 3.7% of Callodine Capital Management LP's investment portfolio, making the stock its 10th largest position. Callodine Capital Management LP's holdings in Sanofi were worth $22,515,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of SNY. Accent Capital Management LLC acquired a new position in shares of Sanofi during the first quarter valued at $29,000. Eastern Bank lifted its stake in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares during the period. Golden State Wealth Management LLC lifted its stake in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares during the period. Brentview Investment Management LLC acquired a new position in shares of Sanofi during the first quarter valued at $42,000. Finally, UMB Bank n.a. lifted its stake in shares of Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after acquiring an additional 264 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Trading Down 0.9%

Shares of Sanofi stock traded down $0.46 during trading hours on Friday, hitting $49.48. The company's stock had a trading volume of 2,437,389 shares, compared to its average volume of 2,321,432. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12. The stock has a 50 day moving average of $48.81 and a 200 day moving average of $51.61. The company has a market capitalization of $121.50 billion, a PE ratio of 11.89, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter last year, the company earned $1.73 earnings per share. The firm's revenue was down 7.0% compared to the same quarter last year. Analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Morgan Stanley set a $56.00 price objective on Sanofi in a report on Monday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a report on Tuesday, August 5th. Three equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.